Abstract | BACKGROUND: METHODS: RESULTS: The median FR+CTC level in lung cancers (10.5 CTC units/3 mL blood) was significantly higher than that of the non-malignant group (5.9 CTC units/3 mL blood, P<0.0001). No significant difference in FR+CTC level was observed between patients with different age, gender, and pathological subtype (P>0.05), except for clinical stage (stages I-III versus stage IV: P=0.0169). With 7.9 CTC units/3 mL blood as the cut-off threshold, FR+CTC showed superior sensitivity (78.7%) and specificity (81.7%) in the diagnosis of lung cancers. The detection rate of FR+CTC was significantly higher compared to CEA (24.0%), CYFRA21-1 (48.0%), and NSE (16.0%). The diagnostic efficiency of FR+CTC was similar in stage I lung cancers (n=25, sensitivity =68.0% and specificity =90.1%). CONCLUSIONS: Our results support that FR+CTC is an independent and efficacious biomarker in the diagnosis of lung cancers. FR+CTC detection can be used to assist in early-stage thoracic cancer diagnosis.
|
Authors | Jingbo Liu, Min Han, Hongyu Huang |
Journal | Translational cancer research
(Transl Cancer Res)
Vol. 8
Issue 4
Pg. 1242-1248
(Aug 2019)
ISSN: 2219-6803 [Electronic] China |
PMID | 35116866
(Publication Type: Journal Article)
|
Copyright | 2019 Translational Cancer Research. All rights reserved. |